Generated by AI
OKYO Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropathic corneal pain and inflammatory eye diseases. The company concentrates on ophthalmology and corneal health, with research programs aimed at conditions such as dry eye disease, allergic conjunctivitis, uveitis, and ocular pain. Its pipeline includes urcosimod, an investigational candidate being studied for multiple eye-related indications, and OK-201, another development-stage therapy for ocular pain. OKYO Pharma Ltd. operates as a research and development business in the healthcare sector, targeting unmet needs in diseases affecting the cornea and anterior segment of the eye. Based in London and incorporated in Guernsey, the company plays a specialized role in the biopharmaceutical market by advancing non-opioid and non-steroidal treatment approaches for complex eye disorders.
Website35a Albemarle St
London, W1S 4JE
United Kingdom
The latest articles about OKYO.
LONDON and NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the Stifel 2026 Healthcare Conference November 10–12, 2026. Robert J. Dempsey, Chief Executive Officer, is scheduled to present at 9:20 a.m. ET on Thursday, November 12, 2026, at the Stifel 2026 Hea
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Summary of Jul 8's posts. Generated by AI.
Summary of Feb 9's posts. Generated by AI.
Summary of Oct 5's posts. Generated by AI.
Investors talking about OKYO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.